For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Restriction Endonuclease is an enzyme that cuts DNA at or near specific recognition nucleotide sequences known as restriction sites. They are the enzymes that are found in the bacteria and are harvested from them for their use in research and commercial aspects. Restriction enzymes are commonly classified into four types, which differ in their structure and whether they cut their DNA substrate at their recognition site, or if the recognition and cleavage sites are separate from one another.
Scope of the Report:
This report focuses on the Restriction Endonucleases in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Till date more than 10,000 bacteria are screened for the presence of restriction enzymes and currently there are more than 2,500 restriction enzymes have been discovered along with over 250 distinct specificities in sequences. These enzymes are used in conventional cloning, deciphering epigenetic modifications, construction of DNA libraries and in vivo gene editing. The end users mainly are Academic & Research Institutes, Hospitals & Diagnostic Centers, and Pharmaceutical & Biotechnology companies.
The Restriction Endonuclease industry is relatively concentrated, and the players mainly come from North America and Western Europe. In the world wide, major manufactures mainly are New England Biolabs, Thermo Fisher Scientific, Takara Bio, Illumina, Agilent Technologies, Roche, GE Healthcare, Promega Corporation, Qiagen, Jena Biosciences and etc.
The worldwide market for Restriction Endonucleases is expected to grow at a CAGR of roughly 5.6% over the next five years, will reach 300 million US$ in 2023, from 210 million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- New England Biolabs
- Thermo Fisher Scientific
- Takara Bio
- Agilent Technologies
- GE Healthcare
- Promega Corporation
- Jena Biosciences
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Type I
- Type II
- Type III
- Type IV
Market Segment by Applications, can be divided into
- Academic & Research Institutes
- Hospitals & Diagnostic Centers
There are 15 Chapters to deeply display the global Restriction Endonucleases market.
Chapter 1, to describe Restriction Endonucleases Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Restriction Endonucleases, with sales, revenue, and price of Restriction Endonucleases, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Restriction Endonucleases, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Restriction Endonucleases market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Restriction Endonucleases sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source